If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns
Goed omgaan met pesten en pestgedrag vraagt een pakket aan maatregelen die zowel preventief als curatief kunnen zijn
military members, teachers, nurses and first responders, including police and firefighters, as well as veterans
Sea salt adds 50mg of sodium per serving
Progress monitoring: Regularly assess patient response to treatment and adjust dosage as clinically indicated
The metabolite of the natural product parthenolide, DMOCPTL, induced ferroptosis via ubiquitination of GPX4 in triple-negative breast cancer cells (TNBC), thus effectively inhibiting breast tumor growth (Ding et al., 2021)